Skip to main content

UC San Diego scientists debut Greengenes2, a massive reference database that could be used to reconcile years of microbiome studies. Two leading sequencing techniques are no longer at odds, thanks to an international effort led by scientists at University of California San Diego. In a study published July 27, 2023 in Nature Biotechnology, the researchers debuted a new reference database called Greengenes2. The database makes it possible to compare and combine microbiome data derived from either 16S ribosomal RNA gene amplicon (16S) or shotgun metagenomics sequencing techniques.

Greengenes2 could improve the discovery of microbiome biomarkers

“This is a significant moment in microbiome research, as we’ve effectively rescued over a decade’s worth of 16S data that might have otherwise become obsolete in the modern world of shotgun sequencing,” said senior author Rob Knight, PhD, professor in the departments of Pediatrics at UC San Diego School of Medicine and Bioengineering and Computer Science at UC San Diego Jacobs School of Engineering. “Standardizing results across these two methods will significantly improve our chances of discovering microbiome biomarkers for health and disease.”

Microbiome studies depend on scientists’ ability to identify which microorganisms are present in a sample. To do this, they sequence the genetic information in the sample and compare it to reference databases that list which sequences belong to which organisms. 16S and shotgun sequencing are the two techniques most widely used in microbiome research, but they often yield different results.

Shotgun sequencing

“Many researchers assumed that data from 16S and shotgun sequencing were simply too different to ever be integrated,” said first author of the study Daniel McDonald, PhD, scientific director of The Microsetta Initiative at UC San Diego School of Medicine. “Here we show that is not the case, and provide a reference database that researchers can now use to do just that.”

The original Greengenes database has been widely used in the microbiome field for well over a decade. It was the reference database used by notable projects includes the National Institutes of Health Human Microbiome Project, the American Gut Project, the Earth Microbiome Project, and many others.

Gene sequencing

However, one of its fundamental limitations was that it relied on the sequence of a single gene, 16S, to identify the organisms in a sample. This well-studied gene has long been used as a taxonomic marker, with each organism having its own 16S “barcode.” This method can describe the contents of a microbiome sample with genus-level resolution, but it cannot always identify specific species or strains of microbes, which is important for clinical work.

Modern microbiome studies have since transitioned to using shotgun sequencing, which looks at DNA from all over the organisms’ genomes, rather than focusing on only one gene. This powerful approach gives researchers more species-level specificity and also provides insight into the microbes’ function.

Scientists often attributed the discrepancies between the two techniques to differences in the way the samples are prepared in the lab. However, the new study demonstrates that incompatibilities between the two techniques arise from differences in computation, where a better reference database allows for the same conclusions to be drawn from both methods.

This addresses an important issue in the reproducibility of microbiome research and allows the re-use of data from millions of samples in older studies.

Greengenes2 will help standardize findings

In trying to resolve these incompatibilities, the researchers first expanded the Web of Life whole genome database. They then used several new computational tools developed by co-author Siavash Mirarab, Ph.D., associate professor at UC San Diego Jacobs School of Engineering, to integrate existing high-quality full-length 16S sequences into the whole-genome phylogeny.

Using another machine learning tool developed by Mirarab’s group, they placed 16S fragments from over 300,000 microbiome samples. The result was an expansive reference database that both 16S and shotgun sequencing data could be mapped onto.

To confirm whether Greengenes2 would help standardize findings from either sequencing technique, the researchers acquired both 16S and shotgun sequencing data from the same human microbiome samples and analyzed them both against the backdrop of the Greengenes2 phylogeny. The results from both techniques showed highly correlated diversity assessments, taxonomic profiles, and effect sizes — something researchers had not seen before.

“Through Greengenes2, a huge repository of 16S data can now be brought back into the fold and even combined with modern shotgun data in new meta-analyses,” said McDonald. “This is a major step forward in improving the reproducibility of microbiome studies and strengthening physicians’ ability to draw clinical conclusions from microbiome data.”

Researchers, study details, and references

Co-authors include: Yueyu Jiang, Metin Balaban, Kalen Cantrell, Antonio Gonzalez, Giorgia Nicolaou, Se Jin Song and Andrew Bartko, all at UC San Diego, as well as Qiyun Zhu at Arizona State University, James T. Morton at the National Institutes of Health, Donovan H. Parks and Philip Hugenholtz at The University of Queensland, Søren Karst at Columbia University, Mads Albertsen at Aalborg University, Todd DeSantis at Second Genome, Aki S. Havulinna, Pekka Jousilahti, Teemu Niiranen and Veikko Salomaa at the Finnish Institute for Health and Welfare, Susan Cheng at Brigham and Women’s Hospital and Cedars-Sinai Medical Center, Mike Inouye at University of Cambridge and Baker Heart and Diabetes Institute, Mohit Jain at Sapient Bioanalytics and Leo Lahti at University of Turku.

This work was funded, in part, by the National Science Foundation (grants XSEDE BIO210103 and RAPID 20385.09), the National Institutes of Health (grants 1R35GM142725, U19AG063744, U24DK131617, DP1-AT010885), the Emerald Foundation 3022, Danone Nutricia Research, the Center for Microbiome Innovation and the intramural research program of the Eunice Kennedy Shriver National Institute of Child Health and Human Development.
Full link to study: https://www.nature.com/articles/s41587-023-01845-1

Disclosures: Rob Knight is a consultant and advisory board member with equity and income in BiomeSense related to the proposed PHS-funded research.

Mila Black

Mila Black

Mila is the ultimate health addict. She studied BSC health sciences at WITS University in South Africa, and is currently taking a gap year to blog about changing the way we see healthcare.

Longevity Live is a digital publisher AND DOES NOT OFFER PERSONAL HEALTH OR MEDICAL ADVICE. IF YOU’RE FACING A MEDICAL EMERGENCY, CALL YOUR LOCAL EMERGENCY SERVICES IMMEDIATELY, OR VISIT THE NEAREST EMERGENCY ROOM OR URGENT CARE CENTER. YOU SHOULD CONSULT YOUR HEALTHCARE PROVIDER BEFORE STARTING ANY NUTRITION, DIET, EXERCISE, FITNESS, MEDICAL, OR WELLNESS PROGRAM.

This content, developed through collaboration with licensed medical professionals and external contributors, including text, graphics, images, and other material contained on the website, apps, newsletter, and products (“Content”), is general in nature and for informational purposes only and does not constitute medical advice; the Content is not intended to be a substitute for professional medical advice, diagnosis, or treatment.

Always consult your doctor or other qualified healthcare provider with any questions you may have regarding a medical condition, procedure, or treatment, whether it is a prescription medication, over-the-counter drug, vitamin, supplement, or herbal alternative.

Longevity Live makes no guarantees about the efficacy or safety of products or treatments described in any of our posts. Any information on supplements, related services and drug information contained in our posts are subject to change and are not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects.

Longevity does not recommend or endorse any specific test, clinician, clinical care provider, product, procedure, opinion, service, or other information that may be mentioned on Longevity’s websites, apps, and Content.